Cancer nanotheranostics: A review of the role of conjugated ligands for overexpressed receptors

Ramzy, Lydia; Nasr, Maha; Metwally, Abdelkader A.; Awad, Gehanne A.S.

doi:10.1016/j.ejps.2017.04.005

Cited by 93 publications

(55 citation statements)

References 303 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Thus, targeting is a central goal in nanotechnologies for drug formulation. For instance, folateconjugated PEGylated liposomes containing vincristine showed greater tumor growth inhibition than standard vincristine formulations (Ramzy et al, 2017). In active targeting, the receptor−ligand relationship is exploited.…”

Section: Introductionmentioning

confidence: 99%

“…For this purpose, appropriate ligands are used to target receptors over-synthesized by cancer cells (Ramzy, Nasr, Metwally, & Awad, 2017), such as folate receptors (Zwicke, Mansoori, & Jeffery, 2012). For instance, folateconjugated PEGylated liposomes containing vincristine showed greater tumor growth inhibition than standard vincristine formulations (Ramzy et al, 2017). In addition, when these nanosystems are PEGylated, duration in the systemic circulation is increased and the therapeutic effects can be further improved (Mishra, Nayak, & Dey, 2016).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Efficacy of targeted liposomes and nanocochleates containing imatinib plus dexketoprofen against fibrosarcoma

Çoban

Değim

Yılmaz³

et al. 2019

Drug Development Research

View full text Add to dashboard Cite

The main challenges in treating cancer using chemotherapeutics are insufficient dose at the target site and the development of drug resistance, while higher doses can induce side effects by damaging nontarget tissues. Combinatorial drug therapy may overcome these limitations by permitting lower doses and more specific targeting, thereby mitigating drug resistance and nontarget side effects. Recent reports indicate that nonsteroidal anti-inflammatory drugs (NSAIDs) have anticancer potential and can be used together with conventional chemotherapeutics to improve efficacy and safety. In the present study, imatinib mesylate and dexketoprofen trometamol were selected as model drugs to develop targeted surface-modified liposome and nanocochleate formulations for fibrosarcoma treatment. The physicochemical properties and in vitro efficacy of various formulations were evaluated by measurement of particle size distribution, polydispersity index, zeta potential, encapsulation efficiency, diffusion through Caco-2 cells, and toxicity in culture. Selected formulations were then evaluated in fibrosarcoma-bearing model mice by histopathological observations and tyrosine kinase receptor inhibition assays.The most effective formulation on the fibrosarcoma model was a PEGylated nanocochleate formulation. These findings provide a foundation for developing more effective formulations and chemotherapeutic strategies for the treatment of fibrosarcoma and other types of cancer.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Efficacy of targeted liposomes and nanocochleates containing imatinib plus dexketoprofen against fibrosarcoma

Çoban

Değim

Yılmaz³

et al. 2019

Drug Development Research

View full text Add to dashboard Cite

show abstract

“…It has been reported that many conjugated ligands have been used for modifying theranostic nanomedicines for targeting tumor overexpressed receptor. 32 Here, we selected H 7 K(R 2 ) 2 , a tumor-specific, pH-responsive peptide, as the targeting ligand which could respond at an acidic tumor microenvironment by exhibiting CPP characteristics. We previously proved that H 7 K(R 2 ) 2 could respond to acidic pH in MCF-7, C6, and U87 MG cell lines.…”

Section: Discussionmentioning

confidence: 99%

The theranostic efficiency of tumor-specific, pH-responsive, peptide-modified, liposome-containing paclitaxel and superparamagnetic iron oxide nanoparticles

Zheng¹,

Ren²,

Zhang³

et al. 2018

IJN

View full text Add to dashboard Cite

BackgroundIn the present study, the tumor-specific, pH-responsive peptide H7K(R2)2-modified, theranostic liposome-containing paclitaxel (PTX) and superparamagnetic iron oxide nanoparticles (SPIO NPs), PTX/SPIO-SSL-H7K(R2)2, was prepared by using H7K(R2)2 as the targeting ligand, SPIO NPs as the magnetic resonance imaging (MRI) agent, PTX as antitumor drug.MethodsThe PTX/SPIO-SSL-H7K(R2)2 was prepared by a thin film hydration method. The characteristics of PTX/SPIO-SSL-H7K(R2)2 were evaluated. The targeting effect, MRI, and antitumor activity of PTX/SPIO-SSL-H7K(R2)2 were investigated detail in vitro and in vivo in human breast carcinoma MDA-MB-231 cell models.ResultsOur results of in vitro flow cytometry, in vivo imaging, and in vivo MR imaging confirmed the pH-responsive characteristic of H7K(R2)2 in MDA-MB-231 cell line in vitro and in vivo. The results of in vivo MRI and in vivo antitumor activity confirmed the theranostic effect of PTX/SPIO-SSL-H7K(R2)2 in MDA-MB-231 tumor-bearing model.ConclusionConsidering all our in vitro and in vivo results, we conclude that we developed targeting modified theranostic liposome which could achieve both role of antitumor and MRI.

show abstract

“…Several excellent reviews on the development of nanotheranostics for cancer imaging and therapy have been published previously . This review aims to summarize recent advances in NPs for use in multimodality oncological imaging and treatment, providing examples of the research underway, including methods which have reached the preclinical or clinical trial stage.…”

Section: Introductionmentioning

confidence: 99%

Recent advances in the development of nanoparticles for multimodality imaging and therapy of cancer

Liu

Anderson

Lan

et al. 2019

Medicinal Research Reviews

View full text Add to dashboard Cite

This review explores recent work directed toward the development of nanoparticles (NPs) for multimodality cancer imaging and targeted cancer therapy. In the growing era of precision medicine, theranostics, or the combined use of targeted molecular probes in diagnosing and treating diseases is playing a particularly powerful role. There is a growing interest, particularly over the past few decades, in the use of NPs as theranostic tools due to their excellent performance in receptor target specificity and reduction in off-target effects when used as therapeutic agents. This review discusses recent advances, as well as the advantages and challenges of the application of NPs in cancer imaging and therapy.

show abstract

Cancer nanotheranostics: A review of the role of conjugated ligands for overexpressed receptors

Cited by 93 publications

References 303 publications

Efficacy of targeted liposomes and nanocochleates containing imatinib plus dexketoprofen against fibrosarcoma

Efficacy of targeted liposomes and nanocochleates containing imatinib plus dexketoprofen against fibrosarcoma

The theranostic efficiency of tumor-specific, pH-responsive, peptide-modified, liposome-containing paclitaxel and superparamagnetic iron oxide nanoparticles

Recent advances in the development of nanoparticles for multimodality imaging and therapy of cancer

Contact Info

Product

Resources

About